Logo image of MPLT

MAPLIGHT THERAPEUTICS INC (MPLT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MPLT - US56565P1030 - Common Stock

16.06 USD
-0.95 (-5.58%)
Last: 1/7/2026, 8:00:01 PM
16.07 USD
+0.01 (+0.06%)
After Hours: 1/7/2026, 8:00:01 PM
Fundamental Rating

2

Overall MPLT gets a fundamental rating of 2 out of 10. We evaluated MPLT against 530 industry peers in the Biotechnology industry. MPLT has a great financial health rating, but its profitability evaluates not so good. MPLT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MPLT has reported negative net income.
MPLT had a negative operating cash flow in the past year.
MPLT Yearly Net Income VS EBIT VS OCF VS FCFMPLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

MPLT's Return On Assets of -154.27% is on the low side compared to the rest of the industry. MPLT is outperformed by 84.91% of its industry peers.
MPLT's Return On Equity of -203.52% is on the low side compared to the rest of the industry. MPLT is outperformed by 68.30% of its industry peers.
Industry RankSector Rank
ROA -154.27%
ROE -203.52%
ROIC N/A
ROA(3y)-64.6%
ROA(5y)N/A
ROE(3y)-96.44%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MPLT Yearly ROA, ROE, ROICMPLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -50 -100

1.3 Margins

MPLT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MPLT Yearly Profit, Operating, Gross MarginsMPLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for MPLT remains at a similar level compared to 1 year ago.
There is no outstanding debt for MPLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MPLT Yearly Shares OutstandingMPLT Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
MPLT Yearly Total Debt VS Total AssetsMPLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

MPLT has an Altman-Z score of 13.14. This indicates that MPLT is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of MPLT (13.14) is better than 85.66% of its industry peers.
MPLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.14
ROIC/WACCN/A
WACCN/A
MPLT Yearly LT Debt VS Equity VS FCFMPLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

MPLT has a Current Ratio of 4.89. This indicates that MPLT is financially healthy and has no problem in meeting its short term obligations.
MPLT's Current ratio of 4.89 is in line compared to the rest of the industry. MPLT outperforms 56.60% of its industry peers.
MPLT has a Quick Ratio of 4.89. This indicates that MPLT is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.89, MPLT perfoms like the industry average, outperforming 57.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.89
Quick Ratio 4.89
MPLT Yearly Current Assets VS Current LiabilitesMPLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for MPLT have decreased strongly by -39.26% in the last year.
EPS 1Y (TTM)-39.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MPLT is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -28.37% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-246.02%
EPS Next 2Y-41.87%
EPS Next 3Y-28.37%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MPLT Yearly EPS VS EstimatesMPLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MPLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MPLT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MPLT Price Earnings VS Forward Price EarningsMPLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MPLT Per share dataMPLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

MPLT's earnings are expected to decrease with -28.37% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.87%
EPS Next 3Y-28.37%

More info and screens

0

5. Dividend

5.1 Amount

MPLT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MAPLIGHT THERAPEUTICS INC

NASDAQ:MPLT (1/7/2026, 8:00:01 PM)

After market: 16.07 +0.01 (+0.06%)

16.06

-0.95 (-5.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners8.33%
Inst Owner ChangeN/A
Ins Owners4.2%
Ins Owner Change91.97%
Market Cap700.86M
Revenue(TTM)N/A
Net Income(TTM)-129.76M
Analysts88.89
Price Target31.62 (96.89%)
Short Float %4.65%
Short Ratio2.92
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)1.91%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-21.39%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 10.99
P/tB 10.99
EV/EBITDA N/A
EPS(TTM)-3.13
EYN/A
EPS(NY)-3.77
Fwd EYN/A
FCF(TTM)-2.32
FCFYN/A
OCF(TTM)-2.31
OCFYN/A
SpS0
BVpS1.46
TBVpS1.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -154.27%
ROE -203.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.6%
ROA(5y)N/A
ROE(3y)-96.44%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 79.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.89
Quick Ratio 4.89
Altman-Z 13.14
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)107.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.63%
EPS Next Y-246.02%
EPS Next 2Y-41.87%
EPS Next 3Y-28.37%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-44.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-102.74%
EBIT Next 3Y-39.22%
EBIT Next 5YN/A
FCF growth 1Y-51.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.55%
OCF growth 3YN/A
OCF growth 5YN/A

MAPLIGHT THERAPEUTICS INC / MPLT FAQ

What is the fundamental rating for MPLT stock?

ChartMill assigns a fundamental rating of 2 / 10 to MPLT.


Can you provide the valuation status for MAPLIGHT THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to MAPLIGHT THERAPEUTICS INC (MPLT). This can be considered as Overvalued.


How profitable is MAPLIGHT THERAPEUTICS INC (MPLT) stock?

MAPLIGHT THERAPEUTICS INC (MPLT) has a profitability rating of 0 / 10.


Can you provide the financial health for MPLT stock?

The financial health rating of MAPLIGHT THERAPEUTICS INC (MPLT) is 8 / 10.